Progressive multifocal leukoencephalopathy in multiple sclerosis topical collection on demyelinating disorders

Current Neurology and Neuroscience Reports

Volumn 13, Issue 12, 2013, Pages

  Chalkley, Joshua J ^a   Berger, Joseph R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alemtuzumab; JC virus; Multiple sclerosis; Mycophenolate mofetil; Natalizumab; Progressive multifocal leukoencephalopathy; Rituximab

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; CYCLOPHOSPHAMIDE; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MEFLOQUINE; MIRTAZAPINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; RITUXIMAB; TOPOTECAN;

ARTICLE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; MORTALITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPOVAVIRUS; PATHOGENESIS; PLASMAPHERESIS; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; VIRUS IDENTIFICATION; COMPLICATION; PATHOLOGY; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; RISK; VIROLOGY;

HUMANS; MULTIPLE SCLEROSIS; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PROGNOSIS; RISK;

EID: 84890541041     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0408-6     Document Type: Article

References (51)

1. Astrom KE, Mancall EL, Richardson Jr EP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain. 1958;81:93-111.
2. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984;2(2):299-313.
3. Bernick C, Gregorios JB. Progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome. Arch Neurol. 1984;41:780-2.
4. Britton CB, Miller JR. Neurologic complications in acquired immunodeficiency syndrome (AIDS). Neurol Clin. 1984;2:315-39.
5. Snider WD et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol. 1983;14:403-18.
6. Berger JR et al. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med. 1987;107:78-87.
7. Berger JR et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4:59-68.
8. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369-74.
9. Langer-Gould A et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375-81.
10. Van Assche G et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362-8.
11. Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf. 2010;33:969-83.
12. Bechtel M, Sanders C, Bechtel A. Neurological complications of biologic therapy in psoriasis: a review. J Clin Aesthet Dermatol. 2009;2:27-32.
13. Grinyo J, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90(12):1521-7.
14. von Geldern G et al. PML-IRIS in a patient treated with brentuximab. Neurology. 2012;79:2075-7.
15. Wagner-Johnston ND, et al. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012;53(11):2283-6.
16. Neff RT et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008;86:1474-8.
17. Cavanaugh J et al. Cerebral dymyelination associated with disorders of the reticuloendothelial system. Lancet. 1959;2:524-9.
18. Silverman L, Rubinstein LJ. Electron microscopic observations on a case of progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl). 1965;5:215-24.
19. ZuRhein G. Particles resembling papovavirions in human cerebral demyelinating disease. Science. 1965;148:1477-9.
20. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis. 1973;127:467-70.
21. Berger JR. Modeling PML, pathogenesis. Curr Opin Neurol. 2011;24:262-7.
22. Elphick GF et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306:1380-3.
23. Padgett BL, Walker DL. Virologic and serologic studies of progressive multifocal leukoencephalopathy. Prog Clin Biol Res. 1983;105:107-17.
24. Gorelik L et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295-303.
25. Bozic C et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742-50.
26. Matos A et al. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol. 2010;82:494-504.
27. Monaco MC et al. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol. 1998;72:9918-23.
28. Berger JR et al. JC virus detection in bodily fluids: Clues to transmission. Clin Infect Dis. 2006;43(1):e9-12.
29. Rossi A et al. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol. 2007;79:408-12.
30. Chang H et al. High incidence of JC viruria in JC-seropositive older individuals. J Neurovirol. 2002;8:447-51.
31. Bofill-Mas S, Girones R. Role of the environment in the transmission of JC virus. J Neurovirol. 2003;9 Suppl 1:54-8.
32. Knowles WA et al. The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leucoencephalopathy. Clin Diagn Virol. 1995;4:183-94.
33. Berger JR et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. Aids. 1992;6:837-41.
34. Fedele CG et al. Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. J Neurovirol. 2003;9:551-8.
35. Major EO. Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med. 2009;361:1041-3.
36. BiogenIdec. PML incidence in patients receiving Tysabri (natalizumab). Medical information 2013. Available at: http://medinfo.biogenidec.com (accessed 8 August 2013).
37. Berger JR, Khalili K. The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med. 2012;12:495-503.
38. Houff SA et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med. 1988;318:301-5.
39. Bonig H et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008;111:3439-41.
40. Krumbholz M et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71:1350-4.
41. Perkins MR et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog. 2012;8:e1003014.
42. • Zaheer F, Berger JR. Treatment related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Safety. 2012;3:227-39. Excellent recent overview of treatment of PML.
43. Bloomgren G et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-80.
44. Lee P et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57:141-6.
45. Berger JR et al. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74(1):84-90.
46. Major EO, Douek DC. Risk factors for rare diseases can be risky to define: PML and natalizumab. Neurology. 2013;81(10):858-9.
47. • Clifford DB et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438-46. Thorough overview of clinical presentation of PML.
48. Carson KR, Bennett CL. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma. 2009;50:323-4.
49. •• Berger JR et al. PML diagnostic criteria: consensus statement from the American Academy of Neurology Neuroinfectious Disease Section. Neurology. 2013;80:1430-8. Definitive AAN American Academy of Neurology consensus statement of PML diagnosis.
50. Yousry TA et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72:779-87.
51. Biogen Idec. Natalizumab safety update. Available at: http://medinfo.biogenidec.com (accessed 20 August 2013).